|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Obatoclax>> Market Analysis Reports |
Market Analysis Reports of Obatoclax |
|
Obatoclax mesilate (CAS 803712-79-0) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of Obatoclax mesilate (CAS 803712-79-0) December 2024 CAS 803712-79-0 Obatoclax mesilate Chemical Report & Database ... Report & Database This Obatoclax mesilate Chemical World Consumption ... & Database definitions: Name: Obatoclax mesilate: Obatoclax-mesilate; 2-[2-[(3,5-Dimethyl-1H-pyrrol ... Chemical or Reaction Intermediate The Obatoclax mesilate Report & Database gives ... Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A Summary: The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report ... Therapeutic Class Overview: Treating Refractory Hematological Malignancies Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs ... ASCO 2012: Promise Of Drugs for Relapsed/ Refractory Multiple Myeloma (RR MM) To Unfold ... (PhIII), Onyx’s Carfilzomib (PhIII), Teva’s Obatoclax, Abbott/PDLI’s Elotuzumab, JNJ’s Siltuximab ... |